Halozyme Therapeutics
HALO
Source: the SEC Form 13F filings of the managers we follow, latest for Q2 2026. How we use them
Value held
$3.3m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Managers holding it, by quarter
1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Who holds it
| Torray Investment Partners | 0.4%$3.0m | Added +1.4% |
| Pzena Investment Management | 0.0%$317k | Unchanged |
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 11,900 | $1.3m |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 4,810 | $520k |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 3,090 | $337k |
| 8 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 200 | $22k |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 10,300 | $1.2m |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 8,600 | $955k |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 900 | $102k |
| 7 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 200 | $23k |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 9,920 | $1.1m |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 6,000 | $656k |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 2,300 | $248k |
| 6 Oct 2026 | Torley HelenPRESIDENT AND CEO | ▼ Sold | 1,780 | $197k |
| 1 Oct 2026 | Posard Matthew L.Director | ▼ Sold | 3,300 | $358k |
| 1 Oct 2026 | Posard Matthew L.Director | ▼ Sold | 1,100 | $121k |
| 1 Oct 2026 | Posard Matthew L.Director | ▼ Sold | 730 | $78k |
| 1 Oct 2026 | Posard Matthew L.Director | ▼ Sold | 100 | $11k |
| 16 Sep 2026 | Posard Matthew L.Director | ▼ Sold | 8,896 | $961k |
| 16 Sep 2026 | Posard Matthew L.Director | ▼ Sold | 4,000 | $436k |
| 16 Sep 2026 | Posard Matthew L.Director | ▼ Sold | 3,100 | $329k |
| 16 Sep 2026 | Posard Matthew L.Director | ▼ Sold | 3,000 | $320k |
About the company
- Sector
- Health care · Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Shares outstanding
- 113m at 31 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$54.8m2013
$135m2015
$317m2017
$196m2019
$443m2021
$829m2023
$1.4bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $1.4bn | $317m |
| 2024 | $1.0bn | $444m |
| 2023 | $829m | $282m |
| 2022 | $660m | $202m |
| 2021 | $443m | $403m |
| 2020 | $268m | $129m |
| 2019 | $196m | −$72.2m |
| 2018 | $152m | −$80.3m |
| 2017 | $317m | $63.0m |
| 2016 | $147m | −$103m |
| 2015 | $135m | −$32.2m |
| 2014 | $75.3m | −$68.4m |
| 2013 | $54.8m | −$83.5m |